|
PRDX3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64035451888367E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.34514621663584E-12 |
| Normal-vs-Stage2 |
1.61779999999778E-05 |
| Normal-vs-Stage3 |
3.67594843453389E-13 |
| Normal-vs-Stage4 |
2.36777264461807E-12 |
| Stage1-vs-Stage2 |
3.131000E-01 |
| Stage1-vs-Stage3 |
3.320400E-02 |
| Stage1-vs-Stage4 |
7.737600E-03 |
| Stage2-vs-Stage3 |
2.574200E-02 |
| Stage2-vs-Stage4 |
5.461200E-03 |
| Stage3-vs-Stage4 |
3.696000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
8.40210000000452E-05 |
| Normal-vs-Asian |
1.92030000012444E-07 |
| Caucasian-vs-AfricanAmerican |
4.100000E-01 |
| Caucasian-vs-Asian |
2.466800E-01 |
| AfricanAmerican-vs-Asian |
9.819400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.17605924998543E-12 |
| Normal-vs-Female |
1.90014670664596E-12 |
| Male-vs-Female |
3.124200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.98279195682017E-12 |
| Normal-vs-Age(41-60Yrs) |
3.13304937549219E-13 |
| Normal-vs-Age(61-80Yrs) |
4.99170005330285E-09 |
| Normal-vs-Age(81-100Yrs) |
8.248800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.319800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.047000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.308400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.745600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.329600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.951200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.465600E-01 |
| Classical-VS-Follicular |
7.56769999999962E-05 |
| Classical-VS-Other |
6.728800E-01 |
| Classical-VS-Normal |
1.6251444634463E-12 |
| Tall-VS-Follicular |
1.171130E-04 |
| Tall-VS-Other |
2.940800E-01 |
| Tall-VS-Normal |
7.93390020348284E-10 |
| Follicular-VS-Other |
3.489000E-01 |
| Follicular-VS-Normal |
6.959600E-04 |
| Other-VS-Normal |
7.696300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.87319945613262E-10 |
| Normal-vs-N1 |
6.05648864393515E-12 |
| N0-vs-N1 |
2.821500E-02 |
|
|
